All Stories

  1. COVID 19 Study, Drug Selection and Development
  2. Anticancer Drug Combinations: Different Strategies Used in the Clinic
  3. Cancer Bioinformatics, New Chapter of Personalized Medicine
  4. Pulmonary nodules, knowledge renovation and comprehensive studies
  5. Personalized Oncology: Scientific and Technical Approaches
  6. Advances in Cancer Therapeutics and Genomics for Improved Patient Outcomes
  7. Magnetic water and clinical cancer chemotherapy
  8. Nursery Services in Future
  9. Human suicide, clinical treatment overview
  10. Sexually transmitted disease diagnosis and treatments, risk factors from beyond
  11. Human suicide, risk factors and new perspective
  12. Suicide study, new approaches
  13. Human suicide, molecular framework
  14. COVID-19 knowledge and therapeutics, past, present and future
  15. Artificial intelligence for advancing nursery service
  16. Treatment improvements by pediatric Theranostics
  17. COVID-19 conception advances, epidemics, pathology and therapeutics
  18. Withdrawn: Professor Bin Xu, A Legendary Pharmacologist in People’s Republic of China
  19. Sialic Acids and Cancer: Pathophysiological Association between Metastatic Progress and Treatment
  20. Anticancer Drug Development, Pharmaceutical Progress
  21. Human Suicide, Biomedical Knowledge Advances
  22. Type 2 Diabetes Treatments in Countries of Different Economic Status
  23. Human suicide, biomedical knowledge and therapeutic advances
  24. Human Suicide, an Overview of Management Strategies
  25. COVID-19 Research, Public Health and Biomedical Basis
  26. Human Suicide, Management Landscape
  27. Anticancer Drug Development: Evaluative Architecture
  28. COVID-19 Study: A New Principle Discovery
  29. COVID-19 Study, Diagnostic and Therapeutic Transition
  30. Antimetastatic Drug, Pharmacologic Challenge and Opportunity
  31. Nursery services advances, global campaign
  32. Different approaches to bone transplantation surgery
  33. Bone Metastasis Diagnosis, Blood Biomarker Detections
  34. Anti-metastatic drug development, overview and perspectives
  35. Educational Perspectives for Nursery
  36. Is Tau Molecule Regarded as a Risk Factor for Human Suicide?
  37. Drug Sensitivity Testing for Cancer Therapy, Technique Analysis and Trends
  38. Suicide Curative Treatment Study and Drug Development
  39. Pulmonary nodules, is there any pathogenesis evidence?
  40. HIV/AIDS Curability Study, Different Approaches and Drug Combination
  41. Pulmonary nodules, surgery or other medication
  42. Bone Metastasis and Circulation Biomarkers Profiling Towards Personalized Cancer Medicine
  43. Pulmonary Nodules, Surgery or Other Medication
  44. Anti-Metastatic Drug Developments, Utility of More Animal Models
  45. Several approaches for anticancer drug development progress
  46. Drug Sensitivity Testing for Cancer Therapy, Key Areas
  47. COVID-19 infection for metabolic abnormal human beings
  48. Fundamental knowledge for nurses 
  49. Nursery promotion, education and system updating
  50. Cancer Bone Metastasis, Diagnostic Insights and Drug Selection
  51. Covid-19 Study, Pathology and Therapeutics
  52. Acupuncture for Bone Disease Treatments, Modern Approaches
  53. Cancer Bone Metastasis, Experimental Study
  54. Neuropsychiatric Approaches for Human Suicide Prediction and Management
  55. Osteoporosis Targeting, Possible Breakthroughs
  56. Neuropsychiatric insights for human suicide
  57. Bone Cancer and Metastasis Trials, Drug Treatment
  58. Neurobiology for human suicide
  59. Bone Disease Treatment Study, Major Pathways
  60. Pathology Study for Human Suicide
  61. Nursery activity and quality, chemistry between doctors and nurses
  62. Nursery education, narrow-range or wide-range
  63. Anticancer drug development, challenge and dilemma
  64. Life Origin on Earth, Knowledge Development
  65. HIV/AIDS treatment, therapeutic strategy break throughs
  66. Nursery education for diabetes
  67. Suicide Risks and Prevention, Neuropathogenic Study
  68. Medical Treatments for Chronic or Aggressive Diseases, Palliative Therapy and Nursery
  69. General information for nursery
  70. Historical analysis of suicide
  71. Drug sensitivity testing, a unique drug selection strategy
  72. Natural drug cancer treatments, strategies from herbal medicine to chemical or biological drugs
  73. Medical treatments for incurable diseases, palliative therapy
  74. Life Origin on Earth, Biochemical Approaches
  75. Nursery training, from technique details in schools into medical knowledge education in nursery career
  76. Herbal medicine in new era
  77. Nursery service, quality promotion
  78. Anti-Metastatic Drug Developments, Biomedical Mechanisms and Therapeutic Categorization
  79. Patient’s care and nursery in different diseases
  80. Ebola Therapeutic Study and Future Directions
  81. New HIV/AIDS Therapeutics
  82. Nursery Service in Modern Days
  83. Nursery Education, Capability and Service Promotion
  84. Nursery Science and Conventions
  85. Cancer Bioinformatics in Cancer Therapy
  86. Individualized Cancer Therapy
  87. Human Suicide Risk and Treatment Study
  88. Type 2 Diabetes Treatment and Drug Development Study
  89. Hypotheses for Life Origin on Earth, Comparison and Validation
  90. Type 2 Diabetes Study, Introduction and Perspective
  91. Type 2 Diabetes Mellitus Study, A Process of Enigma unraveling
  92. Anthocyanins and its biological & therapeutic characters
  93. Diabetes Prevention and Treatments, a Specific Topic for Modern Medicines
  94. A Critical Appraisal of Different Food Safety and Quality Management Tools to Accomplish Food Safety
  95. Pathology and treatments of obesity
  96. Obesity, Risks and Managements
  97. Keep up the pace of drug development evolution and expenditure
  98. An Overview of Obesity
  99. General Topics in the Field of Personalized Cancer Therapy
  100. Human Suicide Risk Study and Treatment: A Mathematical Approach
  101. Anti-Metastatic Drug Developments: Work Out towards New Direction
  102. Diabetes Mellitus and Male Aging: Pharmacotherapeutics and Clinical Implications
  103. Drug Combination in Clinical Cancer Treatments
  104. General outlook for individualized cancer therapy
  105. Ebola origin and treatment
  106. Different Disciplines in the Field of Suicide Study
  107. Cancer Bioinformatics for Updating Anticancer Drug Developments and Personalized Therapeutics
  108. HAART in HIV/AIDS Treatments
  109. Anticancer Drug Development, System Updating and Global Participations
  110. Life Origin on Earth, What is the Right Answer?
  111. Life Origin on Earth, What is the Right Answer?
  112. Anticancer Drug Development, Getting out from Bottleneck
  113. Anticancer Drug Development, Getting out from Bottleneck
  114. Human suicide study, major disciplines and treatment outcomes
  115. Anticancer drug development
  116. HIV in Human Genomes and Therapeutics
  117. HIV Biotherapy and Natural Chemotherapeutic Agents
  118. Anticancer Drug Combinations, How Far We can Go Through?
  119. Antimetastatic therapy at aberrant sialylation in cancer cells, a potential hotspot
  120. Life Origin on Earth, Insights among Different Arguments
  121. Genetics in Suicide Treatments, Modern Diagnosis Establishments
  122. Diabetes Preventions and Treatments, a Specific Topic for Modern Medicines
  123. Anticancer Drug Development, Breakthroughs are Waiting
  124. Cancer metastasis treatment, a key drawbacks
  125. The suicide treatment, a new model
  126. HIV Vaccine for Prevention and Cure, A Mission Possible
  127. Zika Therapy
  128. HIV vaccine
  129. Discover Natural Chemical Drugs in Modern Medicines
  130. Mathematics in biomedical science
  131. The origin of HIV
  132. Human suicide study
  133. Mathematics or Physics-Majored Students on the Biomedical Fields, Insiders or Outsiders?
  134. Pharmacogenetics of Cancer Therapy
  135. Anticancer Drug Sensitivity Testing
  136. New Perspectives of HIV/AIDS Therapy Study
  137. Antidepressant treatment study
  138. Clinical neoplasm metastasis treatments according to patient's personal conditions.
  139. Assistant cancer treatments in the clinic
  140. Drug sensitivity testing in clinical cancer treatments
  141. Anticancer drug combination in the clinic
  142. Anticancer drug pharmacogenomics in cancer chemotherapy
  143. Cost-effectiveness for personalized cancer therapy
  144. Conclusion
  145. Introduction
  146. Discussion
  147. Cancer biomarker/bioinformatics detection in clinical cancer treatments
  148. Anti-diabetic treatments
  149. Anticancer Drug Combinational Study
  150. The Origins of HIV
  151. Plasma Fibrinogen Concentrations in Patients with Solid Tumors and Therapeutic Improvements by Combining Anticoagulants or Fibrinolytical Agents
  152. Anticancer Drug Combinations, A Big Momentum is Needed
  153. Anticancer Drug Development, a Matter of Money or a Matter of Idea?
  154. Future Perspectives for Controlling Ebola Epidemics
  155. Ebola Origin and Therapies
  156. Cancer Bioinformatics, its Impacts on Cancer Therapy
  157. Copyright
  158. List of figures and tables
  159. Anti-diabetic treatments, patho-therapeutic relation
  160. Origin of Ebola, hypothesis
  161. Personalized Cancer Therapy: A Perspective
  162. Rethink Of Diabetes Treatment and Drug Development
  163. Pharmacogenomics in human suicide prediction and treatments
  164. Cancer metastasis treatment study and drug developments
  165. Challenge for HIV/AIDS therapy
  166. Cost-effectiveness Considerations of Individualized Cancer Chemotherapy
  167. Drug Combinations in Cancer Treatments
  168. New Insights into Individualized Antimetastatic Therapy
  169. Anticancer drugs on serum sialic acid level in mice bearing LLC
  170. Drug Combinations in Cancer Treatments
  171. Genetics in Neural Toxicity of Drugs
  172. Avian flu, pathogenesis and therapeutic study
  173. First Genetic Information Replication in Life Origin on Earth
  174. Origins of Life, A New Cooperative Model
  175. Cancer Metastases and Clinical Therapies
  176. Origins of Life, RNA world or alternative RNA world
  177. Development of Antimetastatic Drugs by Targeting Tumor Sialic Acids
  178. Individualized Cancer Chemotherapy by Detecting Cancer Biomarkers
  179. Antimetastatic Therapies according to Metastatic Cascade
  180. Genetics in antidepressant-induced suicide
  181. Pathology of Drug-induced mania & suicide
  182. Influenza treatment
  183. High Active Anti-retroviral Therapy for HIV/AIDS, Progresses and Drawback
  184. Individualized cancer chemotherapy
  185. High Active Antiretroviral Therapy for HIV/AIDS-Early Intervention or Later Intervention?
  186. The Hypotheses for the Pathogeny of Drug-Induced Mania and Suicide
  187. The Relationship between Tumor Sialic Acids and Neoplasm Metastasis and as a Drug Target
  188. Genomic study of antidepressant-induced suicide
  189. Aberrant sialylation in tumor cells
  190. Anti-mobility of Bisdioxopiperanes against human mammary tumors
  191. Antimetastatic activity and mechanisms of action of Bisdioxopiperazine compounds
  192. Neural toxicity of drugs
  193. Anticancer activity and mechanisms of Bisdioxopiperazines
  194. Different Spontaneous Pulmonary Metastasis Inhibitions against Lewis Lung Carcinoma in Mice by Bisdioxopiperazine Compounds of Different Treatment Schedules
  195. 14C-probimane in the mice bearing LLC
  196. Unsatisfactory design of human AIDS genome research
  197. Antidepressant in Cancer Treatment
  198. AIDS and human genome studies, from a hypothesis to systematic approaches
  199. Antidepressants in Human suicide
  200. Mathematical model in therapeutic risk prediction
  201. Fibrinogen in neoplasm metastasis
  202. Sequencing the whole genome of infected human cells obtained from diseased patients – a proposed strategy for understanding and overcoming AIDS or other deadest virus-infected diseases
  203. Relationship Between Blood Fibrinogen Concentration and Pathological Features of Cancer Patients: A 139-case Clinical Study
  204. Medicinal Chemistry of Probimane and MST-16: Comparison of Anticancer Effects Between Bisdioxopiperazines
  205. Individualized cancer chemotheray
  206. Anti-proliferative and chromosome segregation by probimane and MST-16
  207. Effect of Anti-Cancer Drugs on the Binding of 125I-Fibrinogen to Two Leukaemia Cell Lines In Vitro
  208. Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo
  209. Inhibition of probimane on lipid peroxidation of rabbit and human erythrocytes
  210. Aberration of sialylation in neoplasm metastasis and possible therapeutics
  211. Effects of Cancer Chemotherapy on the Blood Fibrinogen Concentrations of Cancer Patients
  212. Effect of magnetized water on the mice given high doses of antineoplastic drugs
  213. Inhibition of probimane on lipoperoxidation of human red cells in vitro
  214. Enzyme dynamic study on calmodulin Ca++-Mg++-ATPase system of red blood cells inhibited by α-anordrin and probimane
  215. Journal of Clinical and Medical Reviews